OvaGene Oncology licenses the Moffitt Center’s cancer assay IP
Executive Summary
Molecular diagnostics start-up OvaGene Oncology Inc. has licensed exclusive worldwide rights to the H. Lee Moffitt Cancer Center & Research Institute’s IP pertaining to the development and commercialization of microRNA-based cancer drug prediction assays.
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Antisense, Oligonucleotides
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice